Northwestern Events Calendar

Jan
22
2021

From Idea to Therapeutic: A Biopharma, Biotech & VC Perspective

recurring see all events in this series

When: Friday, January 22, 2021
10:00 AM - 11:00 AM Central

Where: Online
Webcast Link

Audience: Faculty/Staff - Post Docs/Docs - Graduate Students

Contact: Sonia Kim   847.467.0446

Group: Innovation and New Ventures Office

Category: Training

Description:

How do I attract industry interest or participation in my therapeutic ideas? 

Please join us for the first INVOForward seminar during which Jim Sullivan (Venture Partner, Orbimed) will discuss a critical element in pursuing a potential therapeutic, namely the validation of the biological rationale, to biopharma and venture groups. Based on his biopharma, biotech and venture capital perspective, Dr. Sullivan will discuss new emerging therapeutic modalities and the importance of both genomics and additional data in target validation. He will share vignettes across a number of programs with respect to offer his perspectives on getting therapeutic projects funded by biopharma, biotech and venture. 

This seminar is part of the INVOForward Therapeutics lecture series focused on helping Northwestern researchers gain insight into how to build a compelling therapeutic data package. While the INVOForward mentorship program has four select faculty-led teams participating, the lectures are open to Northwestern Faculty, Post-docs and Students.

Other INVOForward lectures may be found here.

 

OUR SPEAKER

Jim Sullivan, Ph.D.

Dr. Sullivan is a Venture Partner with Orbimed and the CEO of two start-up companies focused on the development of novel therapeutic agents for neurological conditions including Parkinson’s disease. Previously, he was the Vice President of Research at Abbvie where he was responsible for AbbVie’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. These include products on the market for HCV (Mavyret and Viekira), the-first-in- class Bcl2 selective inhibitor, Venclexta for hematological cancers, a new oral agent for patients with rheumatoid arthritis, RINVOQ, and multiple compounds currently in Phase II or III clinical trials. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Jim is an adjunct faculty member at Northwestern University and serves on the board of a number of companies and foundations including Regis Technologies, Genomics Medicine Ireland, Genuity Science, MATTER Healthcare Incubator, Chicago Biotechnology Accelerator and the Pistoia Alliance. He earned his bachelor's degree and Ph.D. in biochemistry from Trinity College Dublin and conducted post-doctoral research in neurobiology at Northwestern University.

 

INVOForward Therapeutics is a 6-week Northwestern mentorship program designed to accelerate biomedical commercialization at the university.

If you have any questions, please email INVOForward@northwestern.edu

 

Register More Info Add to Calendar

Add Event To My Group:

Please sign-in